Rick Hancock

Rick Hancock was appointed to the Board of Directors as Executive Chairman in January 2022. Rick has worked in the Biotechnology Industry for over 35 years, including 20 years with various CDMOs in operational and executive roles.

Most recently, he served as Interim President and CEO at Avid Bioservices and prior to that, as President and CEO of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, plasmid DNA and parenteral products. In addition to Avid and Althea, Rick has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company) and is currently the Executive Chairman of Argonaut Manufacturing Services, Inc., a privately held CDMO serving the biotechnology and life sciences industries.

He also serves on the Board of Directors of Tempo Therapeutics, a privately held company, focused on tissue regeneration and vaccine technology, as well as Avid Biosciences, a public CDMO with expertise in Biologics and Viral Vector manufacturing services. Rick received a B.A. in Microbiology from Miami University.